ArticleCell research2015
Regenerative medicine: targeted genome editing in vivo.
Article in Cell research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- NIMA-related kinase family at the nexus of skeletal development and congenital arthrogryposis: coordinated regulation of cell cycle and ciliary dynamics.Frontiers in genetics · 2026Review
- In vivo correction of cystic fibrosis mediated by PNA nanoparticles.Science advances · 2022Article
- Electrochemical Evaluation of Tumor Development via Cellular Interface Supported CRISPR/Cas Trans-Cleavage.Research (Washington, D.C.) · 2022Article
- The Potential of iPSCs for the Treatment of Premature Aging Disorders.International journal of molecular sciences · 2017Review
- Current and future therapies for inherited cholestatic liver diseases.World journal of gastroenterology · 2017Review
- Interspecies chimeric complementation for the generation of functional human tissues and organs in large animal hosts.Transgenic research · 2016Review
- Neurogenethics: An emerging discipline at the intersection of ethics, neuroscience, and genomics.Applied & translational genomics · 2015Review
Corrections and comments
- Comment on
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The CRISPR/Cas system has proven to be a powerful gene editing tool both in vitro and in vivo. A recent flurry of studies of in vivo gene editing using the CRISPR/Cas system bring bright prospects in creating animal models and targeted gene therapy of human genetic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.